iTolerance, Inc. to Present at Biotech Showcase(TM) 2024
iTolerance, Inc., an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, and Northway Biotech, an end-to-end biologics CDMO, entered into a partnership agreement for the manufacture of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the iTOL-100 platform technology. The SA-FasL fusion protein has shown great potential in preclinical studies, establishing durable, localized immune tolerance, and enabling implanted tissue, organoid, or cell therapy to function as a viable replacement for damaged native cells.